{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"YIUCAHIOICYGOA-WNBFYKTCSA-N","prefName":"CP 42,096","symbol":"CP 42,096","iupacName":"(6aR,9R,10aR)-6,6-dimethyl-3-(5-phenylpentan-2-yloxy)-6a,7,8,9,10,10a-hexahydrobenzo[c]chromene-1,9-diol","aliases":["CP 42,096","CP-42,096"],"cas":null,"pubchemCid":"10070164","chebiId":null,"smiles":"CC(CCCC1=CC=CC=C1)OC2=CC(=C3[C@@H]4C[C@@H](CC[C@H]4C(OC3=C2)(C)C)O)O","molecularFormula":"C26H34O4","molecularWeight":410.5,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/10070164"}},"classification":{"family":"scra","familyLabel":"Synthetic cannabinoid (SCRA)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origin (pharmaceutical research → illicit market)","summaryFr":"No biosynthetic route: CP 42,096 is produced by no living organism described in the consulted sources. It belongs to synthetic chemistry alone, in the class of hydrogenated benzo[c]chromenes bearing an alkyl ether at position 3.","originNote":"Wholly synthetic molecule. No consulted source describes it in hemp or in any other living organism: it is known only as a laboratory compound, used in pharmacological research on cannabinoid receptors.","discovered":""},"pharmacology":{"summaryFr":"CP 42,096 belongs to the CP series of synthetic cannabinoids. The tertiary Wikipedia pointer attributes it to Pfizer in the 1980s. A study by Koe et al., published in 1985, describes it as a cannabimimetic that increases, in mice and in vivo, the binding of [3H]flunitrazepam to the brain, and that shows analgesic activity. No affinity constant for CB1 or CB2 receptors is published in the consulted sources, and no human data was found there. The compound is not named in the French narcotics list; its structure matches the generic clause for benzo[c]chromenes at three of its four substituted positions, but the position 9 hydroxyl is not clearly covered by the definition, so its status remains uncertain.","receptorSummaryFr":"Cannabimimetic, hence a presumed agonist of cannabinoid receptors. No affinity constant for CB1 or CB2 is published in the consulted sources. In the study by Koe et al. (1985), the compound increases in vivo binding of [3H]flunitrazepam to mouse brain and shows analgesic activity, with a potency higher than that of delta-9-THC in that assay.","binding":[{"target":"CB1","efficacy":"full_agonist","relativeActivity":20,"reported":"aucune constante d'affinité trouvée dans les sources consultées (activité in vivo, Koe et coll., 1985)","confidence":"medium"}],"references":[{"label":"Koe et coll., amélioration de la liaison cérébrale du [3H]flunitrazépam et activité analgésique des cannabimimétiques de synthèse, European Journal of Pharmacology 1985","pmid":"2986995","doi":"10.1016/0014-2999(85)90421-2","url":"https://pubmed.ncbi.nlm.nih.gov/2986995/"},{"label":"ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexe IV, clause des benzo[c]chromènes, décisions des 22 mai et 3 juin 2024)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"ANSM, décision du 22 mai 2024 portant modification de la liste des substances classées comme stupéfiants","pmid":null,"doi":null,"url":"https://ansm.sante.fr/actualites/decision-du-22-05-2024-portant-modification-de-la-liste-des-substances-classees-comme-stupefiants"},{"label":"ANSM, décision du 3 juin 2024 portant modification de la liste des substances classées comme stupéfiants","pmid":null,"doi":null,"url":"https://ansm.sante.fr/actualites/decision-du-03-06-2024-portant-modification-de-la-liste-des-substances-classees-comme-stupefiants"},{"label":"INCB, Liste verte 2026 au titre de la Convention de 1971 (entrées PT 002 et PH 003)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, CID 10070164, CP 42,096 (identifiants et propriétés)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/10070164"},{"label":"Wikipédia EN, article CP 42,096 (repère tertiaire)","pmid":null,"doi":null,"url":"https://en.wikipedia.org/wiki/CP_42%2C096"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":10},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":5},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":10},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":10},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":5}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"evolving","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No harmonised control measure at European Union level is documented for CP 42,096 in the consulted sources: control therefore rests with the member states. At international level, it is not listed in the INCB Green List 2026, which does list tetrahydrocannabinols and HHC under different structures (entries PT 002 and PH 003).","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"CP 42,096 is not named in the consolidated list of substances classified as narcotics, updated on 16 February 2026. It could fall under the generic clause for benzo[c]chromene derivatives, in annex IV of that list (decisions of 22 May and 3 June 2024): its ring A is fully hydrogenated, and its positions 1 (hydroxyl), 3 (alkoxy chain) and 6 (two alkyl groups) match the permitted substituents. Its position 9, however, bears a direct hydroxyl group, which the definition does not list among the permitted substituents (ketone, alkyl, hydroxyalkyl or alkoxy), and the text does not state with certainty whether it falls under 'hydroxyalkyl'. The status is therefore uncertain. It is neither CBN, nor THCV, nor THCA, the cannabinoids excluded by the clause.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Koe et coll., amélioration de la liaison cérébrale du [3H]flunitrazépam et activité analgésique des cannabimimétiques de synthèse, European Journal of Pharmacology 1985","pmid":"2986995","doi":"10.1016/0014-2999(85)90421-2","url":"https://pubmed.ncbi.nlm.nih.gov/2986995/"},{"label":"ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexe IV, clause des benzo[c]chromènes, décisions des 22 mai et 3 juin 2024)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"ANSM, décision du 22 mai 2024 portant modification de la liste des substances classées comme stupéfiants","pmid":null,"doi":null,"url":"https://ansm.sante.fr/actualites/decision-du-22-05-2024-portant-modification-de-la-liste-des-substances-classees-comme-stupefiants"},{"label":"ANSM, décision du 3 juin 2024 portant modification de la liste des substances classées comme stupéfiants","pmid":null,"doi":null,"url":"https://ansm.sante.fr/actualites/decision-du-03-06-2024-portant-modification-de-la-liste-des-substances-classees-comme-stupefiants"},{"label":"INCB, Liste verte 2026 au titre de la Convention de 1971 (entrées PT 002 et PH 003)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, CID 10070164, CP 42,096 (identifiants et propriétés)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/10070164"},{"label":"Wikipédia EN, article CP 42,096 (repère tertiaire)","pmid":null,"doi":null,"url":"https://en.wikipedia.org/wiki/CP_42%2C096"}],"meta":{"slug":"cp-42-096","url":"https://en.phytogrammes.com/wiki/cp-42-096","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-13","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}